In the rapidly evolving field of inflammasome therapeutics, the need for innovative approaches to overcome the preclinical and clinical hurdles is more critical than ever.
Discover & Develop Selective, Clinically Validated & Novel Covalent Therapeutics to Expand the Targetable Proteome & Non-Cystine Amino Acid Space in Oncology, Immunology & B
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh